Corrigendum: “Exosomal transfer of miR-501 confers doxorubicin resistance and tumorigenesis via targeting of BLID in gastric cancer” (Cancer Letters (2019) 459 (122–134), (S0304383519303301), (10.1016/j.canlet.2019.05.035))

The authors regret that following the publication of this article, we have noticed that Fig. 5B (7901 501KD + ADR Exo group) had part same area with Fig. 5B (7901 BLID + ADR Exo group). Fig. 5C (7901 501KD + ADR Exo group) had part same area with Fig. 5C (7901 BLID + ADR Exo group). Fig. 5E (7901 + ADR DMSO group) had part same area with Fig. 5E (7901 + ADR 501i + siBLID group), and Fig. 5E (7901 + ADR 501i group) had part same area with Fig. 5F (7901 + ADR 501i group). Fig. 5F (7901 + ADR 501i + siBLID group) had part same area with Fig. 5C (7901 NCi + PBS group). Supplementary Fig. 7C (823 BLID + ADR Exo) group was identical to Fig. 5E (7901 + ADR DMSO) group. We realized the names of these original images had been inadvertently wrongly used. To ensure data accuracy, we looked up the previous original pictures, compared them according to time and groups, and found the correct original pictures to replace the Fig. 5B (7901 501KD + ADR Exo) group, Fig. 5C (7901 BLID + ADR Exo) group, Fig. 5E (7901 + ADR DMSO) group, Fig. 5E (7901 + ADR 501i) group, Fig. 5F (7901 + ADR 501i + siBLID) group, and Supplementary Fig. 7C (823 BLID + ADR Exo) group. The correct Fig. 5 and Supplementary Fig. 7 are shown below. The overall conclusions of this study are not affected by this error. The authors would like to apologize for any inconvenience caused.